Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.36.4539PMID 21859995PMCID PMC3188282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

  2013cited by this paper
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009influential reference
• Palliative care and oncology: growing better together.

  2009cited by this paper
• Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database.

  2009cited by this paper
• FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

  2008cited by this paper
• Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

  2007cited by this paper
• Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin

  2007cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

  2001cited by this paper
• A note on quantifying follow-up in studies of failure time.

  1996cited by this paper
• The asymptotic properties of nonparametric tests for comparing survival distributions

  1981cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Theranostic Iron Oxide Nanoparticles for Controlled Oxaliplatin Release Under Simulated Circulation and Cytotoxicity Evaluation in Colorectal Cancer Cell Lines

  2026cites this paper
• Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in patients with High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT Trial.

  2026cites this paper
• Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

  2025cites this paper
• Critical Evaluation of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

  2025cites this paper
• Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies.

  2025cites this paper
• The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

  2025cites this paper
• Treatment Adherence to Adjuvant Chemotherapy According to the New Standard 3-month CAPOX Regimen in High-risk Stage II and Stage III Colon Cancer: A Population-based Evaluation in The Netherlands.

  2025cites this paper
• Therapeutic potential of stem cells in colorectal cancer management: Current trends and future prospects

  2025cites this paper
• AI Clinical Decision Tools in Multidisciplinary Team Discussions for Colorectal Cancer

  2025cites this paper
• A new fluorescent oxaliplatin(iv) complex with EGFR-inhibiting properties for the treatment of drug-resistant cancer cells

  2025cites this paper
• Risk of second primary malignancies after adjuvant chemotherapy for colon cancer

  2025cites this paper
• Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial

  2025cites this paper
• Benefit of oxaliplatin-based chemotherapy or capecitabine monotherapy in older patients with stage III and high-risk stage II colon cancer: Data from the National Colorectal Cancer Cohort study in China.

  2025cites this paper
• Efficacy and safety of oral 5‐FU‐based adjuvant chemotherapy for geriatric patients with colorectal cancer: Integrated analysis of seven clinical trials conducted at the Japanese Foundation for Multidisciplinary Treatment of Cancer

  2025cites this paper
• Engineering Triphenyl Phosphonium Conjugated Iron Oxide Nanoparticles for Oxaliplatin loading: Application in Cancer Treatment

  2025cites this paper
• Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment

  2025influential citation
• Recommendations of perioperative systemic therapies considering age or comorbidities in the National Comprehensive Cancer Network (NCCN) guidelines and quality of cited evidence.

  2025cites this paper
• Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis

  2025cites this paper
• Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial

  2025influential citation
• The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyridine Single Therapy to the Oxaliplatin Regimen

  2025cites this paper
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

  2025cites this paper
• Adjuvant chemotherapy in older patients with stage II and III colon cancers: Is less more?

  2025cites this paper
• Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis

  2024cites this paper
• Cystathionine-β-synthase expression correlates with tumour progression and adverse prognosis in patients with colon cancer

  2024cites this paper
• The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers

  2024cites this paper
• Updates on the Management of Colorectal Cancer in Older Adults

  2024cites this paper
• SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)

  2024cites this paper
• CAPÍTULO 16 Tratamiento sistémico por estadio tumoral

  2024cites this paper
• Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: How to Select the Most Suitable?

  2024cites this paper
• Value of Real-World Evidence for Treatment Selection: A Case Study in Colon Cancer

  2024cites this paper
• Complete Obstruction, a Real Risk Factor: A Comprehensive Study on Obstruction in Stage IIA Colon Cancer With Propensity Score Matching Analysis.

  2024cites this paper
• Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials

  2024cites this paper
• Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR).

  2024cites this paper
• Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?

  2024cites this paper
• Nodular Hyperplasia Mimicking Colon Cancer Liver Metastasis

  2024cites this paper
• Adjuvant Chemotherapy With UFT/LV Versus UFT/LV Plus PSK in Stage II/III Colorectal Cancer

  2024cites this paper
• Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer

  2024cites this paper
• The role of adjuvant chemotherapy in rectal cancer patients with ypT0-2N0 after neoadjuvant chemoradiotherapy

  2024cites this paper
• Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer.

  2024cites this paper
• Significance of Adjuvant Chemotherapy for Obstructive Colorectal Cancer After Stent Placement: A Multicenter Retrospective Study

  2024cites this paper
• Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence.

  2024cites this paper
• Risk stratification of stage II rectal mucinous adenocarcinoma to predict the benefit of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery

  2024cites this paper
• Mechanism of Preventing Recurrence of Stage II-III Colorectal Cancer Metastasis with Immuno-inflammatory and Hypoxic Microenvironment by a Four Ingredients Chinese Herbal Formula: A Bioinformatics and Network Pharmacology Analysis.

  2024cites this paper
• Neoadjuvant Short- Vs. Long-Course Radiation for Locally Advanced Rectal Cancer: How to Choose

  2024cites this paper
• Essential updates 2022–2023: Surgical and adjuvant therapies for locally advanced colorectal cancer

  2024cites this paper
• Hospital Service Volume as an Indicator of Treatment Patterns for Colorectal Cancer.

  2024cites this paper
• Astragalus polysaccharide ameliorates CD8+ T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation-induced colorectal cancer.

  2024cites this paper
• Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review

  2023cites this paper
• Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy

  2023cites this paper
• High Infiltration of CD203c+ Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer

  2023cites this paper
• Peripheral low-density granulocytes after colorectal cancer surgery in predicting recurrence

  2023cites this paper
• A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

  2023cites this paper
• The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial

  2023cites this paper
• Prise en charge du cancer du côlon après résection curative

  2023cites this paper
• Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?

  2023cites this paper
• Retrospective study of an incisional hernia after laparoscopic colectomy for colorectal cancer

  2023cites this paper
• Association between social background and implementation of postoperative adjuvant chemotherapy for older patients undergoing curative resection of colorectal cancers, sub-analysis of the HiSCO-04 study

  2023cites this paper
• Variations in the Type of Adjuvant Chemotherapy Among Stage III Colon Cancer Patients in England

  2023cites this paper
• Response Prediction after Neoadjuvant Chemotherapy for Colon Cancer Using CT Tumor Regression Grade: A Preliminary Study

  2023cites this paper
• Opportunities on the horizon for the management of early colon cancer.

  2023cites this paper
• Changes in Prescribing Patterns in Stage III Colon Cancer.

  2023cites this paper
• Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

  2023cites this paper
• Management of Older Adults With Colorectal Cancer: The Role of Geriatric Assessment.

  2023cites this paper
• Correlations of age with clinicopathological features, perioperative outcomes and the prognosis in patients with colorectal cancer: a Japanese multicenter study

  2023cites this paper
• Real‐world tolerance and outcomes of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter?

  2023cites this paper
• Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?

  2023cites this paper
• Two tripartite classification systems of CD86+ and CD206+ macrophages are significantly associated with tumor recurrence in stage II-III colorectal cancer

  2023cites this paper
• Clinical application of circulating tumour DNA in colorectal cancer.

  2023cites this paper
• Radiologic T staging of colon cancer: renewed interest for clinical practice

  2023cites this paper
• Adjuvant Chemotherapy Is Associated with Improved Survival for Stage III Colon Cancer When Initiated Beyond 8 Weeks

  2023cites this paper
• Polysaccharides from Chinese herbs as natural weapons against colorectal cancer

  2023cites this paper
• Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study.

  2023cites this paper
• Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks

  2023cites this paper
• Immunotherapy for Colorectal Cancer in the Era of Precision Medicine

  2023cites this paper
• A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study

  2023cites this paper
• Glycoproteomics-based liquid biopsy: translational outlook for colorectal cancer clinical management in Southeast Asia.

  2023cites this paper
• Guidance for Treating the Older Adults with Colorectal Cancer

  2023cites this paper
• N2 Lymph Node Metastasis Is a Useful Predictor of Recurrence in Patients With Stage III Rectal Cancer Undergoing Adjuvant Chemotherapy Using Tegafur–uracil/leucovorin

  2023cites this paper
• Pathologist Validation of a Machine Learning–Derived Feature for Colon Cancer Risk Stratification

  2023cites this paper
• The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II–III Colorectal Cancer: A Retrospective Multi-Center Cohort Study

  2023cites this paper
• NCR, an Inflammation and Nutrition Related Blood-Based Marker in Colon Cancer Patients: A New Promising Biomarker to Predict Outcome

  2022cites this paper
• A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan.

  2022cites this paper
• Adjuvant 5‐Fluorouracil/leucovorin, capecitabine, and oxaliplatin‐related regimens for stage II/III colon cancer patients 66 years or older

  2022cites this paper
• Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

  2022cites this paper
• A prognostic signature based on cuprotosis-related long non-coding RNAs predicts the prognosis and sensitivity to chemotherapy in patients with colorectal cancer

  2022cites this paper
• Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

  2022influential citation
• Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

  2022cites this paper
• A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management

  2022cites this paper
• Identification of the Minimum Combination of Serum microRNAs to Predict the Recurrence of Colorectal Cancer Cases

  2022cites this paper
• Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancer

  2022cites this paper
• Factors Associated With Adjuvant Chemotherapy Noncompliance and Survival in Older Adults With Stage III Colon Cancer

  2022cites this paper
• Exploratory study on relative dose intensity and reasons for dose reduction of adjuvant CAPOX therapy in elderly patients with colorectal cancer.

  2022cites this paper
• Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients

  2022cites this paper
• Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study

  2022cites this paper
• Impact of Medical Treatments of Colorectal Cancer on Female Fertility and Oncofertility Issues in Young Women with Non-Metastatic Colorectal Cancer: State of the Art

  2022influential citation
• Oxaliplatin-Induced Sinusoidal Obstruction Syndrome Masquerading as Colorectal Liver Metastasis: A Case Report

  2022cites this paper
• A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.

  2022cites this paper
• The Clinical Impact of Apical Lymph Node Metastasis of Colorectal Cancer After Curative Resection

  2022cites this paper
• Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis

  2022influential citation
• Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial

  2022cites this paper